Abd-Elfattah A S, Jessen M E, Hanan S A, Tuchy G, Wechsler A S
Department of Surgery, Medical College of Virginia, Richmond 23298-0532.
Circulation. 1990 Nov;82(5 Suppl):IV341-50.
The aim of this study was to determine the dual role of ATP as an energy substrate and as a major source of oxygen-derived free-radical-mediated reperfusion injury by using adenine nucleoside blocker, p-nitrobenzylthioinosine (NBMPR), and adenosine deaminase inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA). In a randomized study, 16 dogs were instrumented with minor-axis LTZ-piezoelectric crystals and intraventricular pressure transducers to monitor, off bypass, left ventricular performance by using a sensitive and load-independent index of contractility (slope of the stroke work-end-diastolic length relation). Hearts were subjected to 60 minutes of normothermic global ischemia and 120 minutes of reperfusion. Normal saline without (Group 1, n = 8) or with (Group 2, n = 8) NBMPR and EHNA was infused in three boluses into the cardiopulmonary bypass reservoir before ischemia and reperfusion. Transmural serial biopsies were obtained before and during ischemia and reperfusion and analyzed for myocardial adenine nucleotide pool intermediates by using high-performance liquid chromatography. In the control group, three hearts developed ischemic contracture and another three hearts exhibited cardiogenic shock during reperfusion. In the EHNA/NBMPR-treated group, left ventricular performance recovered within 30 minutes of reperfusion (p less than 0.05 vs. control). Myocardial ATP was depleted to 20% of normal in both groups by the end of ischemia (p less than 0.05). Intramyocardial adenosine in the EHNA/NBMPR-treated group was 12-fold greater (15.09 +/- 1.6 nmol/mg protein) than the control group at the end of the ischemic period (p less than 0.05). Inosine was about fourfold higher in the control group (19.07 +/- 1.50 nmol/mg protein) compared with the drug-treated group (p less than 0.05). During reperfusion, myocardial ATP levels increased to approximately 50% of normal in the EHNA/NBMPR group while remaining depressed (20% of normal) in the control group. Thus, despite the dramatic loss of myocardial ATP during ischemia, complete recovery of ventricular performance and significant repletion of ATP during reperfusion were observed when adenosine transport and deamination were modulated during ischemia and reperfusion. These results suggest that 1) the myocardium may have more ATP than is needed for basic cardiac functions and 2) washout of ATP diffusible catabolites is detrimental to ventricular performance during reperfusion. Specific blockade of nucleoside transport resulted in complete functional recovery despite low but critical ATP levels.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究的目的是通过使用腺嘌呤核苷阻滞剂对硝基苄基硫代肌苷(NBMPR)和腺苷脱氨酶抑制剂赤型-9-(2-羟基-3-壬基)腺嘌呤(EHNA),来确定ATP作为能量底物以及作为氧衍生的自由基介导的再灌注损伤主要来源的双重作用。在一项随机研究中,16只犬被植入短轴LTZ压电晶体和心室内压力传感器,以便在体外循环停止后,通过使用敏感且与负荷无关的收缩性指标(每搏功-舒张末期长度关系的斜率)来监测左心室功能。心脏经历60分钟的常温全心缺血和120分钟的再灌注。在缺血和再灌注前,将不含(第1组,n = 8)或含有(第2组,n = 8)NBMPR和EHNA的生理盐水分三次推注到体外循环储液器中。在缺血和再灌注前及期间获取透壁系列活检组织,并使用高效液相色谱法分析心肌腺嘌呤核苷酸池中间体。在对照组中,3只心脏出现缺血性挛缩,另外3只心脏在再灌注期间表现出心源性休克。在EHNA/NBMPR治疗组中,再灌注30分钟内心室功能恢复(与对照组相比,p < 0.05)。缺血结束时,两组心肌ATP均耗竭至正常水平的20%(p < 0.05)。缺血期末,EHNA/NBMPR治疗组心肌内腺苷比对照组高12倍(15.09±1.6 nmol/mg蛋白)(p < 0.05)。对照组肌苷比药物治疗组高约4倍(19.07±1.50 nmol/mg蛋白)(p < 0.05)。再灌注期间,EHNA/NBMPR组心肌ATP水平增加至正常水平的约50%,而对照组仍处于降低状态(正常水平的20%)。因此,尽管缺血期间心肌ATP显著丧失,但当在缺血和再灌注期间调节腺苷转运和脱氨时,观察到心室功能完全恢复且再灌注期间ATP显著补充。这些结果表明:1)心肌的ATP可能多于基本心脏功能所需;2)ATP可扩散分解代谢产物的清除对再灌注期间的心室功能有害。尽管ATP水平低但至关重要,核苷转运的特异性阻断仍导致功能完全恢复。(摘要截短于400字)